PLoS ONE · 2016 · 96 citations · 42 references
MedicineOncologyPathologyMolecular OncologyNeoplasiaProteomicsCancer BiomarkersCancer ProteomicsMass Spectrometry-based ProteomicsPancreatic CancerProteomic BiomarkersQuantitative ProteomicsEarly DiagnosisLiquid Chromatography-mass SpectrometryLiquid Chromatography-mass Spectrometry AnalysisMultiple Reaction MonitoringPancreatic Cancer DetectionPlasma Protein BiomarkersSelected Reaction MonitoringTumor Biomarker Discovery
Pancreatic cancer is one of the most lethal tumors, and reliable detection of early-stage pancreatic cancer and risk diseases for pancreatic cancer is essential to improve the prognosis. As 260 genes were previously reported to be upregulated in invasive ductal adenocarcinoma of pancreas (IDACP) cells, quantification of the corresponding proteins in plasma might be useful for IDACP diagnosis. Therefore, the purpose of the present study was to identify plasma biomarkers for early detection of IDACP by using two proteomics strategies: antibody-based proteomics and liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomics. Among the 260 genes, we focused on 130 encoded proteins with known function for which antibodies were available. Twenty-three proteins showed values of the area under the curve (AUC) of more than 0.8 in receiver operating characteristic (ROC) analysis of reverse-phase protein array (RPPA) data of IDACP patients compared with healthy controls, and these proteins were selected as biomarker candidates. We then used our high-throughput selected reaction monitoring or multiple reaction monitoring (SRM/MRM) methodology, together with an automated sample preparation system, micro LC and auto analysis system, to quantify these candidate proteins in plasma from healthy controls and IDACP patients on a large scale. The results revealed that insulin-like growth factor-binding protein (IGFBP)2 and IGFBP3 have the ability to discriminate IDACP patients at an early stage from healthy controls, and IGFBP2 appeared to be increased in risk diseases of pancreatic malignancy, such as intraductal papillary mucinous neoplasms (IPMNs). Furthermore, diagnosis of IDACP using the combination of carbohydrate antigen 19-9 (CA19-9), IGFBP2 and IGFBP3 is significantly more effective than CA19-9 alone. This suggests that IGFBP2 and IGFBP3 may serve as compensatory biomarkers for CA19-9. Early diagnosis with this marker combination may improve the prognosis of IDACP patients.
42
Rebecca L. Siegel, Jiemin Ma, Zhaohui Zou et al. · CA A Cancer Journal for Clinicians · 2014 · 11.6K citations · Full text
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Peter Y. Park, Teresa A. Goldin, John C. S. Chang et al. · Case Reports in Oncology · 2015 · 5.3K citations · Full text
Junichi Kamiie, Sumio Ohtsuki, Ryo Iwase et al. · Pharmaceutical Research · 2008 · 479 citations
Liver, gallbladder, extrahepatic bile ducts, and pancreas
Marisa T. Carriaga, Donald E. Henson · Cancer · 1995 · 451 citations · Full text